Evolving Treatment Options in First-Line Metastatic Urothelial Carcinoma (mUC) and Muscle Invasive Bladder Cancer (MIBC)
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with unit
Memorial Deadline: Wednesday 28th, January 2026
External Deadline: Saturday 31st, January 2026
Description
Astellas and Pfizer via the “Pfizer-Astellas Alliance” are collaborating to offer a new grant opportunity seeking proposals for independent medical education initiatives that bring awareness and knowledge to healthcare professionals regarding current medical education gaps in the locally advanced / metastatic urothelial cancer (la/mUC) and the rapidly evolving muscle invasive bladder cancer (MIBC) treatment landscapes. Therefore, grant applications with a focus on how emerging data could be practice changing for those who treat patients with bladder cancer are requested.
This competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer and /or Astellas must not be involved in any aspect of project development, nor the conduct of the independent education program.
Date RFP Issued: Dec 19, 2025
Geographic Scope: Ex-US multi-regional with priority given to Europe, Canada, China, Middle East, Russia, Turkey, Latin America, Asia-Pacific countries, Australia and Taiwan
Clinical Area: Genitourinary Cancer focussing on locally advanced/ metastatic urothelial cancer (la/mUC) and muscle-invasive bladder cancer (MIBC)
Link to full RFP: Evolving Treatment Options in First-Line Metastatic Urothelial Carcinoma (mUC) and Muscle Invasive Bladder Cancer (MIBC)
Application Due Date: Jan 31, 2026
Specific Area of Interest: Examples of educational formats that will be considered under this CGA include, but are not limited to:
- – Multi-activity or tiered education that builds over time, such as a series of activities or curriculum-based learning
- – On agenda educational sessions during live conferences or satellite symposia adjacent to major conferences (including those through Winter of 2026/27)
- – Grand Rounds or tumour boards, with a particular focus on multidisciplinary tumour boards
- Case-based workshops focusing on AE management of ADCs and peri-operative therapy decision-making as well as treatment sequencing
- – Expert interviews recorded at live conferences, conference coverage reviews
- – Online articles, training courses, webinars, podcasts
– All learning resources such as videos, infographics, animation - Refer to complete details in the full RFP document. Additionally, applications must be submitted through the Astellas grants portal. If you have questions regarding this RFP or the grant application operational process, please direct them in writing to the Astellas Grants Senior Director, Robyn Baker (GEC@astellas.com), or the Grant Officer, Lori Carpenter (lori.carpenter@pfizer.com) for RFP discussion.